Details

Last Funding Type

Seed

Industries

Health Care,Medical,Pharmaceutical

Founded date

Jan 1, 2010

Number Of Employee

1 - 10

Operating Status

Active

Lipigon Pharmaceuticals is specialized in fat metabolism and develops new blood lipids.

Lipigon is currently focusing on developing drugs directed against the enzyme lipoprotein lipase (LPL). People with low activity at LPL have a higher incidence of elevated blood fats and also related disorders such as insulin resistance and metabolic syndrome. Thanks to Lipigon's expertise in this area, AstraZeneca has chosen to enter into a cooperation agreement with the Company to develop LPL-based pharmaceuticals. Lipigon can receive up to $ 110 million in compensation at achieved milestones related to development and sales.